Aim: The aim of our study was to compare the influence of partial hepatectomy, intra-arterial treatment with 3-BrPA and TACE on regional and distant metastases. In order to achieve our objective, we tested the feasibility of both resection, intra-arterial therapy with 3-BrPA and TACE of VX2 liver cancer in New Zealand White rabbits.
Methods: VX2 tumors were implanted in the left lateral lobe of the liver of 20 rabbits. Tumors were allowed to grow for 14 days. Rabbits were divided in four groups. Group 1 (n=2) was sacrificed 14 days post implantation. Group 2, 3 and 4 (n=6) underwent left lateral hepatectomy, a 1 h intra-arterial infusion with 3-BrPA and TACE respectively. Animals in each group were further subdivided into three groups of two animals each corresponding to the time-point of sacrifice after the procedure (7, 14 and 21 days respectively). After sacrifice, organs were harvested, fixed and analyzed.
Results: Pathologic examination showed lung metastases in all 20 rabbits. Abdominal cavity dissemination was seen in five rabbits in Group 2, two rabbits in Group 3 and all rabbits in Group 4. Kidney metastases were seen in two rabbits treated with TACE.
Conclusion: The VX2 rabbit model of liver cancer is a suitable model to compare the influence of partial hepatectomy, intra-arterial treatment with 3-BrPA and TACE on tumor recurrence in the form of regional and distant metastases. Our results indicate that intra-arterial delivery of 3-BrPA may result in a favorable metastatic profile when compared to both liver resection and TACE.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10585-008-9195-x | DOI Listing |
Eur J Surg Oncol
January 2025
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 510060, Guangzhou, PR China; Department of Liver Surgery, Sun Yat-sen University Cancer Center, 510060, Guangzhou, PR China. Electronic address:
Background: Hepatectomy is the optimal treatment for less than 20 % patients with hepatocellular carcinoma (HCC). A combination of hepatic artery infusion chemotherapy and systemic therapy-based conversion therapy provides a chance of resection for those with unresectable HCC. Yet, the prognosis for those successfully conversion resection is still unknown.
View Article and Find Full Text PDFAnticancer Res
August 2024
Department of Surgery, Kurume University School of Medicine, Kurume, Japan.
Background/aim: The outcome of hepatectomy for a hepatocellular carcinoma (HCC) exceeding 10 cm (i.e., huge HCC) remains unfavorable.
View Article and Find Full Text PDFInt Immunopharmacol
September 2024
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China. Electronic address:
Background: Though atezolizumab plus bevacizumab (A+B) offer promise for unresectable hepatocellular carcinoma (uHCC) treatment, the response rate remains suboptimal. Our previous studies highlighted the potential of transarterial chemoembolization (TACE) when combined with FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) in HCC treatment. This study aims to evaluate the safety and efficacy of A+B plus TACE-HAIC for high tumor burden uHCC (HTB-uHCC).
View Article and Find Full Text PDFWorld J Gastroenterol
May 2024
Department of Surgery, Duke University Medical Center, Durham, NC 27710, United States.
A significant number of patients with hepatocellular carcinoma (HCC) are usually diagnosed in advanced stages, that leads to inability to achieve cure. Palliative options are focusing on downstaging a locally advanced disease. It is well-supported in the literature that patients with HCC who undergo successful conversion therapy followed by curative-intent surgery may achieve a significant survival benefit compared to those who receive chemotherapy alone or those who are successfully downstaged with conversion therapy but not treated with surgery.
View Article and Find Full Text PDFAnn Surg Oncol
August 2024
Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!